Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab

Background Many patients with multiple sclerosis are treated with immunomodulating therapies. Ocrelizumab decreases humoral responses after SARS-CoV-2 vaccination. Therefore, patients are offered additional booster vaccinations to increase these responses. However, it is unknown if an additional boo...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kempen, Zoé L.E., Kummer, Laura Y.L., Wieske, Luuk, Rispens, Theo, Eftimov, Filip, Killestein, Joep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801059/
http://dx.doi.org/10.1016/j.nerep.2022.100072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801059/
http://dx.doi.org/10.1016/j.nerep.2022.100072

Ejemplares similares